Sammenlign metoder

	Adaptiv Fase IV-undersøgelse	Adaptivt randomiseret klinisk forsøg
Fagområde	Epidemiologi	Epidemiologi
Familie	Process / pipeline	Process / pipeline
Oprindelsesår	1990s–2000s (regulatory formalization of adaptive Phase IV designs)	Late 1990s–2000s (widespread adoption post-2010)
Ophavsperson	Adaptive design principles developed by multiple statisticians; Phase IV framework established by regulatory bodies (FDA, EMA) in the late 20th century	Donald Berry and colleagues; formalized by FDA guidance in 2010 and 2019
Type	Adaptive post-marketing clinical study design	Experimental clinical trial design
Oprindelig kilde	Chow, S. C., & Chang, M. (2008). Adaptive Design Methods in Clinical Trials. Chapman and Hall/CRC. ISBN: 978-1584889625	Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36.
Aliasser	adaptive post-marketing surveillance study, adaptive pharmacovigilance study, adaptive Phase IV trial, adaptive post-approval study	adaptive RCT, adaptive trial design, response-adaptive randomization trial, adaptive clinical trial
Relaterede	6	6
Resumé	An Adaptive Phase IV study is a post-marketing surveillance study conducted after a drug or intervention has received regulatory approval, augmented with pre-specified adaptive design elements that allow pre-planned modifications to the study protocol in response to accumulating data. These modifications may include sample size re-estimation, endpoint adjustments, or population enrichment, all governed by statistical rules set before the study begins, preserving scientific integrity while increasing efficiency.	An adaptive randomized clinical trial (adaptive RCT) is a prospective experimental study that uses pre-specified rules to modify one or more trial aspects — such as sample size, allocation ratios, or treatment arms — based on accumulating data collected during the trial itself, while maintaining statistical validity and integrity of the study.